OXFORD BIODYNAMICS PLC Logo

OXFORD BIODYNAMICS PLC

OBD | IL

Overview

Corporate Details

ISIN(s):
GB00BD5H8572 (+2 more)
LEI:
2138005Y1TK258O5U928
Country:
United Kingdom
Address:
3140 ROWAN PLACE, JOHN SMITH DRIVE, OX4 2WB OXFORD
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The company's core technology is the proprietary EpiSwitch® platform, which analyzes 3D genome regulation to discover and develop novel epigenetic biomarkers. Its primary products include the EpiSwitch® PSE, a blood test that detects the likelihood of prostate cancer with high accuracy to reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. Oxford BioDynamics focuses on translating genomic data into clinically actionable insights to improve diagnosis and treatment guidance.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for OXFORD BIODYNAMICS PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-13 08:00
Regulatory News Service
Collaboration with Google Cloud
English 12.0 KB
2025-07-18 16:11
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2025-07-17 08:01
Report Publication Announcement
GenomeWeb to host joint Agilent/OBD presentation
English 18.3 KB
2025-07-17 08:00
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-07-15 18:20
Major Shareholding Notification
Holding(s) in Company
English 23.2 KB
2025-07-15 08:00
Regulatory News Service
Pfizer study on EpiSwitch biomarkers
English 19.7 KB
2025-07-01 16:00
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-06-30 08:00
Earnings Release
Interim Results
English 706.2 KB
2025-06-27 14:30
Major Shareholding Notification
Holding(s) in Company
English 23.3 KB
2025-03-28 11:35
Post-Annual General Meeting Information
Result of AGM
English 12.3 KB
2025-03-17 08:00
Board/Management Information
Board Changes
English 18.2 KB
2025-03-14 18:25
Major Shareholding Notification
Holding(s) in Company
English 23.2 KB
2025-03-13 08:00
Regulatory News Service
Expansion of OBD/Bupa UK insurance partnership
English 26.1 KB
2025-03-05 17:00
Report Publication Announcement
Publication of 2024 Annual Report
English 13.7 KB
2025-03-03 08:00
Remuneration Information
PDMR Dealing / Grant of Share Options
English 67.5 KB

Automate Your Workflow. Get a real-time feed of all OXFORD BIODYNAMICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for OXFORD BIODYNAMICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel ARAN
ARIX BIOSCIENCE PLC Logo United Kingdom ARIX
AroCell AB Logo Sweden AROC
Arterra Bioscience Logo
Develops sustainable active ingredients from plant cell cultures for diverse industries.
Italy ABS
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden ASAP
Ascelia Pharma Logo
Developing novel drugs for rare cancer conditions, including an oral MRI contrast agent.
Sweden ACE
AVACTA GROUP PLC Logo
Developing targeted cancer therapies with a platform that delivers drugs directly to tumors.
United Kingdom AVCT
BenevolentAI Logo
AI-powered platform that analyzes biomedical data to accelerate drug discovery.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL inhibitors for cancer and severe respiratory infections.
Norway BGBIO
BioArctic Logo
Biopharma developing treatments & diagnostics for neurodegenerative diseases like Alzheimer's.
Sweden BIOA